Risk factors for immune-related adverse events: what have we learned and what lies ahead?
Abstract Immune checkpoint inhibitors (ICIs) have heralded the advent of a new era in oncology by holding the promise of prolonged survival in severe and otherwise treatment-refractory advanced cancers. However, the remarkable antitumor efficacy of these agents is overshadowed by their potential for...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
BMC
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/3287374572c741c0b18e6863d74ba14b |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|